Literature DB >> 2888531

Partial parallelism and partial blockade by bryostatin 1 of effects of phorbol ester tumor promoters on primary mouse epidermal cells.

T Sako1, S H Yuspa, C L Herald, G R Pettit, P M Blumberg.   

Abstract

Bryostatin 1, a macrocyclic lactone, functions like the phorbol esters biochemically in binding to and activating protein kinase C. Biologically, however, although it induces some phorbol ester responses such as mitogenesis in Swiss 3T3 cells, it paradoxically blocks the effects of the phorbol esters on differentiation in HL-60 promyelocytic leukemia cells and Friend erythroleukemia cells. Since the phorbol esters induce proliferation and terminal differentiation in distinct subpopulations of epidermal basal cells, we have now examined the action of bryostatin 1 in that system. Bryostatin 1 decreased epidermal growth factor binding and induced ornithine decarboxylase activity, the latter a marker of proliferation. The magnitude of the maximal induction of ornithine decarboxylase was less than for phorbol 12,13-dibutyrate. Bryostatin 1 only transiently caused the morphological change typical of phorbol ester treatment and did not induce transglutaminase or cornified envelope production, markers of the differentiative pathway. Combined treatment with bryostatin 1 and phorbol 12,13-dibutyrate gave similar results to treatment with bryostatin 1 alone, i.e., slight reduction to complete inhibition of phorbol ester action, depending on the response. The mechanism may reflect time dependent block of the protein kinase C pathway by bryostatin 1 in this system; although bryostatin 1 inhibited epidermal growth factor binding at short incubation times (1-2 h), by 4 h of incubation its inhibition was markedly reduced and it correspondingly blocked inhibition of epidermal growth factor binding by phorbol 12,13-dibutyrate. Since induction of terminal differentiation is proposed to be an essential component of phorbol ester mediated tumor promotion in skin, our findings suggest that bryostatin 1 may function as an inhibitor of phorbol ester promotion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2888531

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  18 in total

1.  Synthesis and Biological Evaluation of Fluorescent Bryostatin Analogues.

Authors:  Thomas J Cummins; Noemi Kedei; Agnes Czikora; Nancy E Lewin; Sharon Kirk; Mark E Petersen; Kevin M McGowan; Jin-Qiu Chen; Xiaoling Luo; Randall C Johnson; Sarangan Ravichandran; Peter M Blumberg; Gary E Keck
Journal:  Chembiochem       Date:  2018-03-25       Impact factor: 3.164

2.  Comparison of transcriptional response to phorbol ester, bryostatin 1, and bryostatin analogs in LNCaP and U937 cancer cell lines provides insight into their differential mechanism of action.

Authors:  N Kedei; A Telek; A M Michalowski; M B Kraft; W Li; Y B Poudel; A Rudra; M E Petersen; G E Keck; P M Blumberg
Journal:  Biochem Pharmacol       Date:  2012-11-09       Impact factor: 5.858

3.  Biological activity of the bryostatin analog Merle 23 on mouse epidermal cells and mouse skin.

Authors:  Jessica S Kelsey; Christophe Cataisson; Jinqiu Chen; Michelle A Herrmann; Mark E Petersen; David O Baumann; Kevin M McGowan; Stuart H Yuspa; Gary E Keck; Peter M Blumberg
Journal:  Mol Carcinog       Date:  2016-02-09       Impact factor: 4.784

4.  Different biological effects of the two protein kinase C activators bryostatin-1 and TPA on human carcinoma cell lines.

Authors:  K G Steube; D Grunicke; H G Drexler
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

5.  Differential induction of phosphatidylcholine hydrolysis, diacylglycerol formation and protein kinase C activation by epidermal growth factor and transforming growth factor-alpha in normal human skin fibroblasts and keratinocytes.

Authors:  N J Reynolds; H S Talwar; J J Baldassare; P A Henderson; J T Elder; J J Voorhees; G J Fisher
Journal:  Biochem J       Date:  1993-09-01       Impact factor: 3.857

6.  Modeling of the bryostatins to the phorbol ester pharmacophore on protein kinase C.

Authors:  P A Wender; C M Cribbs; K F Koehler; N A Sharkey; C L Herald; Y Kamano; G R Pettit; P M Blumberg
Journal:  Proc Natl Acad Sci U S A       Date:  1988-10       Impact factor: 11.205

7.  The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

Authors:  P A Wender; J DeBrabander; P G Harran; J M Jimenez; M F Koehler; B Lippa; C M Park; C Siedenbiedel; G R Pettit
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-09       Impact factor: 11.205

8.  Stimulation of phosphatidylcholine synthesis by activators of protein kinase C is dissociable from increased phospholipid hydrolysis.

Authors:  Z Kiss; J Chattopadhyay; G R Pettit
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

9.  Identification, activity, and structural studies of peptides incorporating the phorbol ester-binding domain of protein kinase C.

Authors:  P A Wender; K Irie; B L Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-03       Impact factor: 11.205

Review 10.  Biology of the protein kinase C family.

Authors:  C A O'Brian; N E Ward
Journal:  Cancer Metastasis Rev       Date:  1989-12       Impact factor: 9.264

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.